Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.

Clinical chemistry - 6 Dec 2022

Lee Kwang Seob, Seo Jieun, Lee Choong-Kun, Shin Saeam, Choi Zisun, Min Seungki, Yang Jun Hyuek, Kwon Woo Sun, Yun Woobin, Park Mi Ri, Choi Jong Rak, Chung Hyun Cheol, Lee Seung-Tae, Rha Sun Young

Abstract excerpt

BACKGROUND: Ultra-deep sequencing to detect low-frequency mutations in circulating tumor-derived DNA (ctDNA) increases the diagnostic value of liquid biopsy. The demand for large ctDNA panels for comprehensive genomic profiling and tumor mutational burden (TMB) estimation is increasing; however, few ctDNA panels for TMB have been validated. Here, we designed a ctDNA panel with 531 genes, named TMB500, along with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Cells and Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Genomics and Diagnostics

Share to Circulating Tumor DNA

Share to High-Throughput Nucleotide Sequencing

Share to Liquid Biopsy

Share to Lung Cancer Treatments and Mutations

Share to Mutation

Source

Identifiers

PMID: 36306340
DOI: 10.1093/clinchem/hvac146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.PMID 36306340Read ↗

Analytical evaluation of circulating tumor DNA sequencing assays.Semantic proximity Read ↗

Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing-Based Comprehensive Tumor Profiling in Liquid Biopsy Samples.Semantic proximity Read ↗

Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNASemantic proximity Read ↗

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.Semantic proximity Read ↗

Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumorsSemantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice.Semantic proximity Read ↗

Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoringSemantic proximity Read ↗

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA.Semantic proximity Read ↗

Noninvasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boardsSemantic proximity Read ↗

Ultra-deep sequencing data from a liquid biopsy proficiency study demonstrating analytic validity.Semantic proximity Read ↗

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.